However, cetuximab or nimotuzumab are too expensive to treat for most NPC patients in China, which limits the widespread use of concurrent chemoradiotherapy based on anti-EGFR antibodies in patients with LANPC. Here, EGFR is linked to nasopharyngeal carcinoma.